posted on 2019-02-27, 17:02authored byGayatri Ramasamy
Mesenchymal stem cells (MSCs) are more desirablethan embryonicstem cells(ESCs)for clinical applications, mostly due to reduced ethical concerns, ease in expansion, cellular plasticity, and reduced potential for tumorigenesis. They have the capability to replicate as undifferentiated cells or to differentiate into bone, cartilage, fat, muscle, tendon and marrow stromal therefore, they hold great potential for cell therapies.However, for MSCs to be successfully commercialised,well-defined, reproducible and scalable manufacturing processes need to be developed since thetransition of these studies from the laboratory to industrial scale processes with consistent outputs is a majorchallenge. Since the cellsthemselves may be the final product so the quality of the manufactured cells needs to be ensured throughout the entire bioprocess.In this doctorate, the development of a robust MSCs expansion process using an automated platform was investigated. [Continues.]
Funding
Loughborough University (studentship)
History
School
Aeronautical, Automotive, Chemical and Materials Engineering
This work is made available according to the conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Full details of this licence are available at: https://creativecommons.org/licenses/by-nc-nd/4.0/
Publication date
2019
Notes
A Doctoral Thesis. Submitted in partial fulfilment of the requirements for the award of Doctor of Philosophy of Loughborough University.